INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

NCT00615134 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: enfuvirtide [Fuzeon]
DRUG: Optimized background ARV therapy

Sponsor

Hoffmann-La Roche